Cyclic GMP modulators represent a successful application of network pharmacology with potential indications beyond cardiovascular disease.
Supports broader cGMP modulator exploration beyond cardiovascular disease; leaves open prospective trial validation.
Therapies that modulate cyclic guanosine-3'-5'-monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this rather limited organ-based set of indications. Moreover, the multitude of targets and their apparent interchangeability is a proof-of-concept of network pharmacology.
No takes yet. Share an insight, caveat, or question.
Oettrich et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: